Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the Un ...

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi ...

Ashfields care home in Rackheath donates £386 to Leon D’Souza for vital home improvements as he battles Duchenne Muscular Dystrophy.

Keros Therapeutics (KROS)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency’s site.

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] This call is being recorded on Monday, August 11, 2025. I ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Still others wrote letters to the Food and Drug Administration directly. They demanded the FDA restore access to the drug ...

Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne ...

University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular ...

A Champaign second-grader hopes her family's fundraiser can help a kid in the future have a more "normal" childhood, not ...

Pratteln, Switzerland, 15 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that by mutual agreement the Company and Highbridge Capital Management, LLC (Highbridge) have decided to extend ...